Institutional investors purchased a net $506.6 thousand shares of ENTA during the quarter ended March 2017. This may signal that the smart money is gaining interest in this company as the 70.01% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
FIRST MANHATTAN CO. Bought 394.0 Thousand shares of Enanta Pharmaceuticals In...